Drug intelligence / Profile preview

Candicort

Development stage: Phase 3
Lead developer: Ache Pharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

Candicort is a topical cream that combines the antifungal agent ketoconazole with the corticosteroid betamethasone dipropionate. It is used for the treatment of fungal infections of the skin (mycoses) that are accompanied by inflammation, providing both antifungal action and anti-inflammatory relief. The drug is developed by Ache Laboratorios Farmaceuticos S.A.

Brand names: Candicort

Targets

CYP51A1 (Sterol 14α-demethylase)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Candicort.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candicort.

Explore the full profile